Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510419 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
A Phase 3 study of Migraine, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
- 10
- Study locations
NCT00510419 is a Phase 3 study of Migraine that has completed, run by Pfizer. The registered enrollment target is 73 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00510419, a Phase 3 study of Migraine, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack. The study could take approximately 5 weeks and will include about 3 office visits to the study doctor, the patient will be contacted every 2 weeks until the patient experiences a migraine and uses the auto-injector. The last visit will be done by a telephone follow-up call.
Conditions Studied
Interventions
- DRUG "Investigational"Auto-injector (sumatriptan succinate)
Study Locations (10)
Texas
- Anodyne Headache and Pain Care - Dallas
- Houston Headache Clinic - Houston
- Road Runner Research, LTD - San Antonio
California
- San Francisco Clinical Research Center - San Francisco
Connecticut
- New England Center for Headache - Stamford
Illinois
- Diamond Head Clinic - Chicago
Michigan
- Michigan Head Pain & Neurological Institute - Ann Arbor
Missouri
- Clinvest - Springfield
Pennsylvania
- University of Pittsburgh Headache Center - Pittsburgh
Tennessee
- Wesley Headache Clinic - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510419
The ClinicalTrials.gov registry entry for NCT00510419 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which "Investigational"Auto-injector (sumatriptan succinate) is the first listed.
NCT00510419 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00510419 about?
NCT00510419 is a clinical study titled "A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack". The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack. The study could take approximately 5 weeks and will include about 3 office visits to the study doctor, the patient will be contacted ever...
What is the current status of trial NCT00510419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2007-07. Estimated completion is 2007-12.
What conditions does trial NCT00510419 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT00510419?
The interventions under investigation include: "Investigational"Auto-injector (sumatriptan succinate) (DRUG).
Who is sponsoring clinical trial NCT00510419?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00510419 being conducted?
This trial has 10 study locations across California, Connecticut, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.